Bio-Rad Laboratories, Inc. (BIO) Operating Margin: 9.25%
Is Bio-Rad Laboratories, Inc.’s operating margin high or low?
Bio-Rad Laboratories, Inc.'s operating margin of 9.25% is 34% below its 5-year average of 14.08%, near the low end of its 5-year range (10.47%–17.22%).
The operating margin for Bio-Rad Laboratories, Inc. (BIO) is 9.25% as of Wednesday, June 10, 2026. It is below its 12-month average by 11.69% (10.48%).
BIO Operating Margin Chart
BIO Average Operating Margin Chart
BIO Current vs Average Operating Margin Chart
BIO Operating Margin Metrics
OPERATING MARGIN
9.25%
OPERATING MARGIN AVG TTM
10.48%
OPERATING MARGIN AVG 3Y
12.70%
OPERATING MARGIN AVG 5Y
14.08%
OPERATING MARGIN AVG 10Y
9.63%
OPERATING MARGIN AVG 15Y
10.16%
OPERATING MARGIN AVG 20Y
10.30%
CURRENT VS TTM AVG
-11.69%
CURRENT VS 3Y AVG
-27.19%
CURRENT VS 5Y AVG
-34.31%
CURRENT VS 10Y AVG
-3.93%
CURRENT VS 15Y AVG
-8.92%
CURRENT VS 20Y AVG
-10.19%
BIO Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 9.25% | 10.48% | 12.70% | 14.08% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 11.77% | 9.13% | 12.39% | 13.51% |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 1.32% | 4.35% | -1.93% | -10.04% |
| Baxter International Inc. (BAX) | $10.49B | -2.65% | -1.31% | -6.02% | 0.15% |
| Align Technology, Inc. (ALGN) | $12.56B | 14.44% | 15.23% | 16.08% | 17.45% |
| Hologic, Inc. (HOLX) | $16.97B | 17.49% | 19.66% | 22.41% | 27.16% |
| Moderna, Inc. (MRNA) | $18.40B | -153.35% | -140.72% | -73.36% | -52.24% |
| BioNTech SE (BNTX) | $21.81B | -51.55% | -35.20% | 5.18% | 14.03% |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 28.00% | 28.45% | 28.53% | 27.71% |
| Waters Corporation (WAT) | $23.83B | 17.08% | 28.07% | 28.30% | 28.33% |
Operating Efficiency
Gross Margin
51.9%
Operating Margin
9.3%
Bio-Rad Laboratories, Inc. Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. Operating Margin FAQ
- What is the operating margin for Bio-Rad Laboratories, Inc. (BIO)?
- The operating margin for BIO stock is 9.25%.
- Is Bio-Rad Laboratories, Inc.'s operating margin high or low?
- Bio-Rad Laboratories, Inc.'s operating margin of 9.25% is 34% below its 5-year average of 14.08%, near the low end of its 5-year range (10.47%–17.22%).
- What is the TTM average operating margin for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average operating margin for BIO stock is 10.48%.
- What is the 3Y average operating margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average operating margin for BIO stock is 12.70%.
- What is the 5Y average operating margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average operating margin for BIO stock is 14.08%.
- What is the 10Y average operating margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average operating margin for BIO stock is 9.63%.
- What is the 15Y average operating margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average operating margin for BIO stock is 10.16%.
- What is the 20Y average operating margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average operating margin for BIO stock is 10.30%.
Bio-Rad Laboratories, Inc. Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-12-31 | 10.47% |
| 2024-12-31 | 10.48% |
| 2023-12-31 | 12.65% |
| 2022-12-31 | 17.22% |
| 2021-12-31 | 17.12% |
| 2020-12-31 | 16.55% |
| 2019-12-31 | 9.93% |
| 2018-12-31 | -4.74% |
| 2017-12-31 | 5.40% |
| 2016-12-31 | 2.57% |
| 2015-12-31 | 8.26% |
| 2014-12-31 | 6.90% |
| 2013-12-31 | 7.95% |
| 2012-12-31 | 12.76% |
| 2011-12-31 | 14.23% |
| 2010-12-31 | 14.74% |
| 2009-12-31 | 12.95% |
| 2008-12-31 | 10.37% |
| 2007-12-31 | 9.25% |
| 2006-12-31 | 11.47% |
| 2005-12-31 | 9.76% |
| 2004-12-31 | 9.99% |
| 2003-12-31 | 14.53% |
| 2002-12-31 | 15.39% |
| 2001-12-31 | 13.70% |
| 2000-12-31 | 9.20% |
| 1999-12-31 | 8.84% |
| 1998-12-31 | 7.02% |
| 1997-12-31 | 6.23% |
| 1996-12-31 | 9.96% |
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz